- Home
- NA vs NVCT Comparison
NA vs NVCT Comparison
Compare NA & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NA
- NVCT
- Stock Information
- Founded
- NA 2019
- NVCT 2020
- Country
- NA China
- NVCT United States
- Employees
- NA N/A
- NVCT N/A
- Industry
- NA Semiconductors
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- NA Technology
- NVCT Health Care
- Exchange
- NA Nasdaq
- NVCT Nasdaq
- Market Cap
- NA 109.1M
- NVCT 107.8M
- IPO Year
- NA 2022
- NVCT 2022
- Fundamental
- Price
- NA $7.71
- NVCT $5.49
- Analyst Decision
- NA
- NVCT Strong Buy
- Analyst Count
- NA 0
- NVCT 1
- Target Price
- NA N/A
- NVCT $21.00
- AVG Volume (30 Days)
- NA 464.4K
- NVCT 104.2K
- Earning Date
- NA 09-18-2024
- NVCT 03-04-2025
- Dividend Yield
- NA N/A
- NVCT N/A
- EPS Growth
- NA N/A
- NVCT N/A
- EPS
- NA N/A
- NVCT N/A
- Revenue
- NA $6,991,446.00
- NVCT N/A
- Revenue This Year
- NA N/A
- NVCT N/A
- Revenue Next Year
- NA N/A
- NVCT N/A
- P/E Ratio
- NA N/A
- NVCT N/A
- Revenue Growth
- NA N/A
- NVCT N/A
- 52 Week Low
- NA $2.75
- NVCT $4.44
- 52 Week High
- NA $47.50
- NVCT $12.10
- Technical
- Relative Strength Index (RSI)
- NA 47.50
- NVCT 49.57
- Support Level
- NA $6.99
- NVCT $5.34
- Resistance Level
- NA $9.17
- NVCT $5.89
- Average True Range (ATR)
- NA 1.01
- NVCT 0.51
- MACD
- NA -0.11
- NVCT 0.02
- Stochastic Oscillator
- NA 30.43
- NVCT 33.68
About NA Nano Labs Ltd
Nano Labs Ltd operates as a fabless IC design company and product solution provider in China. It engages in the development of HTC chips, HPC chips, distributed computing and storage solutions, smart-NICs, vision computing chips, and distributed rendering. Its products comprise Cuckoo 1.0 Chip, Cuckoo 2.0 Chip, and Darkbird 1.0 Chip. Majority of the company revenue comes from China.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.